LIDDS AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIDDS.ST research report →
Companywww.liddspharma.com
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations.
- CEO
- Mats Bjorn Wiking
- IPO
- 2014
- Employees
- 1
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $3.36M
- P/E
- -0.85
- P/S
- 0.00
- P/B
- 2.25
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -120.81%
- ROIC
- -366.69%
Growth & Income
- Revenue
- $32.00K · 0.00%
- Net Income
- $-5,938,000 · 85.23%
- EPS
- $-0.04 · 93.10%
- Op Income
- $-6,862,000
- FCF YoY
- 79.14%
Performance & Tape
- 52W High
- $0.20
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.05
- Beta
- -0.27
- Avg Volume
- 194.64K
Get TickerSpark's AI analysis on LIDDS.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LIDDS.ST Coverage
We haven't published any research on LIDDS.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIDDS.ST Report →